Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 11/20 | 0.53 |
| ▸ | TACR2 | P21452 | 8/20 | 0.53 |
| ▸ | TAC3 | Q9UHF0 | 1/20 | 0.52 |
| ▸ | RHOC | P08134 | 4/20 | 0.48 |
| ▸ | RHOA | P61586 | 4/20 | 0.48 |
| ▸ | TACR3 | P29371 | 2/20 | 0.47 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6439853 | 1.00 | TACR1 (0.53) | TACR1TACR2TAC3RHOCRHOA | |
| SCHEMBL5801840 | 0.91 | RHOC (0.59) | TACR1TACR2RHOCRHOAUSP2 | |
| SCHEMBL5918157 | 0.91 | RHOC (0.59) | TACR1TACR2RHOCRHOAUSP2 | |
| SCHEMBL6439775 | 0.91 | RHOC (0.59) | TACR1TACR2RHOCRHOAUSP2 | |
| SCHEMBL6439778 | 0.91 | RHOC (0.59) | TACR1TACR2RHOCRHOAUSP2 | |
| SCHEMBL6441435 | 0.90 | RHOA (0.51) | TACR1RHOCRHOAUSP2CYP3A4 | |
| SCHEMBL6441438 | 0.90 | RHOA (0.51) | TACR1RHOCRHOAUSP2CYP3A4 | |
| SCHEMBL6442803 | 0.89 | RHOA (0.52) | TACR1RHOCRHOASPTLC2USP2 | |
| SCHEMBL6442802 | 0.89 | RHOA (0.52) | TACR1RHOCRHOASPTLC2USP2 | |
| SCHEMBL6440063 | 0.87 | RBP4 (0.50) | TACR1RHOCRHOAUSP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1360184-B1 | PIPERIDINE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-6642226-B2 | Such as cis-(3,5-bis-trifluoromethyl-phenyl)-(4-(4-methyl-piperazin-1-yl),-3-phenyl -piperidin-1-yl)-methanone; for treatment of diseases related to neurokinin receptors | HOFFMAN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20020151547-A1 | Substituted phenyl-piperidine methanone compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151547-A1 | Substituted phenyl-piperidine methanone compounds | TACR1, OPRK1, TACR2 | TACR1 1/4885TACR2 3/4885TAC3 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.